Literature DB >> 28681630

Residual dizziness after successful treatment of idiopathic benign paroxysmal positional vertigo originates from persistent utricular dysfunction.

Toru Seo1, Ko Shiraishi1, Takaaki Kobayashi1, Kitano Mutsukazu1, Takeshi Fujita1, Kazuya Saito1, Hiroyasu Watanabe2, Katsumi Doi1.   

Abstract

OBJECTIVE: We used ocular vestibular evoked myogenic potentials to investigate the relationship between residual dizziness and utricular function following the canalith repositioning procedure for benign paroxysmal positional vertigo.
METHODS: Ocular vestibular evoked myogenic potentials were measured in 44 patients (40 included in analyses, four excluded) with successful results from the canalith repositioning procedure. The patients were examined before treatment and again one week after treatment. We analyzed how various general factors and ocular vestibular evoked myogenic potentials related to residual dizziness.
RESULTS: Residual dizziness was not related to gender, affected side, age, duration of symptoms, recurrence, or the results of the initial ocular vestibular evoked myogenic potential test (p > .05). However, residual dizziness was significantly associated with the results of the second ocular vestibular evoked myogenic potential test (p = .007).
CONCLUSIONS: Residual dizziness after a successful canalith repositioning procedure may be caused by persistent utricular dysfunction.

Entities:  

Keywords:  Residual dizziness; benign paroxysmal positional vertigo; canalith repositioning procedure; oVEMP; utricle

Mesh:

Year:  2017        PMID: 28681630     DOI: 10.1080/00016489.2017.1347824

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  10 in total

Review 1.  Risk factors for residual dizziness in patients with benign paroxysmal positional vertigo after successful repositioning: a systematic review and meta-analysis.

Authors:  Yujie Ke; Xin Ma; Yuanyuan Jing; Tongxiang Diao; Lisheng Yu
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-02-26       Impact factor: 2.503

2.  Low 25-Hydroxyvitamin D Levels Are Associated With Residual Dizziness After Successful Treatment of Benign Paroxysmal Positional Vertigo.

Authors:  Yunqin Wu; Kun Han; Weiwei Han; Zhenyi Fan; Min Zhou; Xiaoxiong Lu; Xiaoxia Liu; Li Li; Liwen Du
Journal:  Front Neurol       Date:  2022-06-22       Impact factor: 4.086

3.  Clinical and cVEMP Evaluation Predict Short-Term Residual Dizziness After Successful Repositioning in Benign Paroxysmal Positional Vertigo.

Authors:  Chun-Yan Jiang; Jing Wu; Liang Shu; Xu-Hong Sun; Hui Pan; Qian Xu; Si-Cheng Wu; Jian-Ren Liu; Yun Li; Wei Chen
Journal:  Front Med (Lausanne)       Date:  2022-05-24

4.  Effects of vestibular rehabilitation, with or without betahistine, on managing residual dizziness after successful repositioning manoeuvres in patients with benign paroxysmal positional vertigo: a protocol for a randomised controlled trial.

Authors:  Yan Hu; Huawei Li; Peixia Wu; Wenzhu Cao
Journal:  BMJ Open       Date:  2019-06-18       Impact factor: 2.692

5.  Risk factors for residual dizziness in patients successfully treated for unilateral benign posterior semicircular canal paroxysmal positional vertigo.

Authors:  Xiuwen Jiang; Lina He; Yinzhe Gai; Chengfang Jia; Wenya Li; Sunhong Hu; Jianguo Tang; Liping Cao
Journal:  J Int Med Res       Date:  2020-12       Impact factor: 1.671

6.  Recovery of Regular Daily Physical Activities Prevents Residual Dizziness after Canalith Repositioning Procedures.

Authors:  Salvatore Martellucci; Andrea Stolfa; Andrea Castellucci; Giulio Pagliuca; Veronica Clemenzi; Valentina Terenzi; Pasquale Malara; Giuseppe Attanasio; Francesco Gazia; Andrea Gallo
Journal:  Int J Environ Res Public Health       Date:  2022-01-03       Impact factor: 3.390

7.  A Review of the Quality of Life after Therapeutic Maneuvers in Patients with Benign Paroxysmal Positional Vertigo.

Authors:  Sertac Yetiser; Ziya Salturk
Journal:  Iran J Otorhinolaryngol       Date:  2021-11

8.  Predictive values of serum estradiol, calcium, and 25-hydroxyvitamin D levels for recurrence of benign paroxysmal positional vertigo in postmenopausal women.

Authors:  Xiaoxiang Zhang; Zongxin Zhang; Xiaoyan Lv
Journal:  Turk J Phys Med Rehabil       Date:  2022-03-01

9.  Elevated red cell distribution width predicts residual dizziness in patients with benign paroxysmal positional vertigo.

Authors:  Ke-Hang Xie; Li-Chun Chen; Ling-Ling Liu; Chu-Yin Su; Hua Li; Run-Ni Liu; Qing-Qing Chen; Jia-Sheng He; Yong-Kun Ruan; Wang-Kai He
Journal:  Front Neurol       Date:  2022-09-01       Impact factor: 4.086

10.  Efficacy of Repositioning Therapy in Patients With Benign Paroxysmal Positional Vertigo and Preexisting Central Neurologic Disorders.

Authors:  Chih-Chung Chen; Hsiao-Shan Cho; Hsun-Hua Lee; Chaur-Jong Hu
Journal:  Front Neurol       Date:  2018-06-29       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.